Primary refractory multiple myeloma: a real-world experience
with 85 cases

J 2020

Primary refractory multiple myeloma: a real-world experience with 85 cases

JURCZYSZYN, A; A WASZCZUK-GAJDA; JJ CASTILLO; K KRAWCZYK; Martin ŠTORK et al.

Základní údaje

Originální název

Primary refractory multiple myeloma: a real-world experience with 85 cases

Autoři

Vydání

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2020, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.280

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1080/10428194.2020.1788014

UT WoS

000546279800001

Klíčová slova anglicky

Double-refractory multiple myeloma; prognosis; treatment response; survival

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2021 10:42, Mgr. Tereza Miškechová

Anotace

V originále

This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.

Citovat

JURCZYSZYN, A; A WASZCZUK-GAJDA; JJ CASTILLO; K KRAWCZYK; Martin ŠTORK; L POUR; L USNARSKA-ZUBKIEWICZ; S POTOCZEK; I HUS; JD VALLS; P HARI; S CHHABRA; M GENTILE; G MIKALA; G VARGA; CS CHIM; M FIALA; R VIJ; N SCHUTZ; M RODZAJ; A POROWSKA; DH VESOLE; A DRUZD-SITEK; J WALEWSKI a AK NOOKA. Primary refractory multiple myeloma: a real-world experience with 85 cases. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2020, roč. 61, č. 12, s. 2868-2875. ISSN 1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2020.1788014.

@article{1740559,
   author = {Jurczyszyn, A and WaszczukandGajda, A and Castillo, JJ and Krawczyk, K and Štork, Martin and Pour, L and UsnarskaandZubkiewicz, L and Potoczek, S and Hus, I and Valls, JD and Hari, P and Chhabra, S and Gentile, M and Mikala, G and Varga, G and Chim, CS and Fiala, M and Vij, R and Schutz, N and Rodzaj, M and Porowska, A and Vesole, DH and DruzdandSitek, A and Walewski, J and Nooka, AK},
   article_location = {LONDON},
   article_number = {12},
   doi = {https://doi.org/10.1080/10428194.2020.1788014},
   keywords = {Double-refractory multiple myeloma; prognosis; treatment response; survival},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   note = {Bez afiliace k MU.},
   title = {Primary refractory multiple myeloma: a real-world experience with 85 cases},
   volume = {61},
   year = {2020}
}

TY  - JOUR
ID  - 1740559
AU  - Jurczyszyn, A - Waszczuk-Gajda, A - Castillo, JJ - Krawczyk, K - Štork, Martin - Pour, L - Usnarska-Zubkiewicz, L - Potoczek, S - Hus, I - Valls, JD - Hari, P - Chhabra, S - Gentile, M - Mikala, G - Varga, G - Chim, CS - Fiala, M - Vij, R - Schutz, N - Rodzaj, M - Porowska, A - Vesole, DH - Druzd-Sitek, A - Walewski, J - Nooka, AK
PY  - 2020
TI  - Primary refractory multiple myeloma: a real-world experience with 85 cases
JF  - LEUKEMIA & LYMPHOMA
VL  - 61
IS  - 12
SP  - 2868-2875
EP  - 2868-2875
PB  - INFORMA HEALTHCARE
SN  - 10428194
N1  - Bez afiliace k MU.
KW  - Double-refractory multiple myeloma
KW  - prognosis
KW  - treatment response
KW  - survival
N2  - This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
ER  -

JURCZYSZYN, A; A WASZCZUK-GAJDA; JJ CASTILLO; K KRAWCZYK; Martin ŠTORK; L POUR; L USNARSKA-ZUBKIEWICZ; S POTOCZEK; I HUS; JD VALLS; P HARI; S CHHABRA; M GENTILE; G MIKALA; G VARGA; CS CHIM; M FIALA; R VIJ; N SCHUTZ; M RODZAJ; A POROWSKA; DH VESOLE; A DRUZD-SITEK; J WALEWSKI a AK NOOKA. Primary refractory multiple myeloma: a real-world experience with 85 cases. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2020, roč.~61, č.~12, s.~2868-2875. ISSN~1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2020.1788014.

Přehled o publikaci